Yokohama City University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Yokohama Japan (1882)

Organization Overview

First Clinical Trial
2003
NCT00190580
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Yokohama City University | Yokohama City University Center Hospital | Yokohama City University Graduate School of Medicine | Yokohama City University Medical Center | Yokohama City University School of Medicine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Asthma (Phase 3)

Atrial Fibrillation (Phase 4)

Behcet Syndrome (Phase 3)

Cardiovascular Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 4)

Essential Hypertension (Phase 4)

Fatty Liver (Phase 2)

Head and Neck Neoplasms (Phase 3)

Hypercholesterolemia (Phase 4)

Hypertension (Phase 4)

Hyperuricemia (Phase 4)

Intestinal Pseudo-Obstruction (Phase 2)

Kidney Diseases (Phase 4)

Liver Diseases (Phase 2)

Mucocutaneous Lymph Node Syndrome (Phase 3)

Myocardial Ischemia (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 34